Compare OEC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OEC | VNDA |
|---|---|---|
| Founded | 1862 | 2002 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.0M | 361.4M |
| IPO Year | 2014 | 2005 |
| Metric | OEC | VNDA |
|---|---|---|
| Price | $7.15 | $5.05 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.56 | ★ $14.90 |
| AVG Volume (30 Days) | 708.2K | ★ 797.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,806,700,000.00 | $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | $2.21 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $4.35 | $4.14 |
| 52 Week High | $11.21 | $9.91 |
| Indicator | OEC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 29.37 |
| Support Level | $6.66 | N/A |
| Resistance Level | $7.70 | $5.46 |
| Average True Range (ATR) | 0.40 | 0.21 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 67.69 | 1.12 |
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.